A Case Report of Envafolimab in the Treatment of Microsatellite Stable (MSS) Metastatic Colon Cancer.

IF 2.7 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

OncoTargets and therapy Pub Date : 2024-11-25 eCollection Date: 2024-01-01 DOI:10.2147/OTT.S473040

Yunshan Yang, Xu Luo, Li Dai, Tong He, Siqi Luo, Yongjin Zhou, Haibin Wang, Zhiqiang Yan, Qian Wang, Xiangren Jin

{"title":"A Case Report of Envafolimab in the Treatment of Microsatellite Stable (MSS) Metastatic Colon Cancer.","authors":"Yunshan Yang, Xu Luo, Li Dai, Tong He, Siqi Luo, Yongjin Zhou, Haibin Wang, Zhiqiang Yan, Qian Wang, Xiangren Jin","doi":"10.2147/OTT.S473040","DOIUrl":null,"url":null,"abstract":"<p><p>Envafolimab is a novel inhibitor for programmed cell death protein-ligand 1 (PD-L1) that can be administered subcutaneously. It has been found to be effective and safe in the treatment of advanced high microsatellite unstable (MSI-H) / mismatch repair deficient (dMMR) solid tumors. Currently, the efficacy of programmed cell death protein-1 (PD-1) / programmed cell death protein-ligand 1 (PD-L1) inhibitors in the treatment of microsatellite stable (MSS) tumors is not clear. We report a case of advanced colon cancer with MSS metastases in bilateral clavicle, mediastinum, retroperitoneum, bilateral hilum, and left side of thoracic 11/12 vertebral body. After 8 months of Envafolimab treatment, there was a significant reduction in metastatic lesions. As of February 1st, 2024, the patient exhibited no significant adverse reactions. The current efficacy evaluation was the partial response (PR), and the overall survival (OS) was more than 12 months. Considering the safety and efficacy of Envafolimab observed in our case, we believe that Envafolimab may be a promising drug for the treatment of MSS metastatic colon cancer.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"1137-1144"},"PeriodicalIF":2.7000,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11606711/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OncoTargets and therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/OTT.S473040","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Envafolimab is a novel inhibitor for programmed cell death protein-ligand 1 (PD-L1) that can be administered subcutaneously. It has been found to be effective and safe in the treatment of advanced high microsatellite unstable (MSI-H) / mismatch repair deficient (dMMR) solid tumors. Currently, the efficacy of programmed cell death protein-1 (PD-1) / programmed cell death protein-ligand 1 (PD-L1) inhibitors in the treatment of microsatellite stable (MSS) tumors is not clear. We report a case of advanced colon cancer with MSS metastases in bilateral clavicle, mediastinum, retroperitoneum, bilateral hilum, and left side of thoracic 11/12 vertebral body. After 8 months of Envafolimab treatment, there was a significant reduction in metastatic lesions. As of February 1st, 2024, the patient exhibited no significant adverse reactions. The current efficacy evaluation was the partial response (PR), and the overall survival (OS) was more than 12 months. Considering the safety and efficacy of Envafolimab observed in our case, we believe that Envafolimab may be a promising drug for the treatment of MSS metastatic colon cancer.

查看原文本刊更多论文

恩伐利单抗治疗微卫星稳定转移性结肠癌1例。

Envafolimab是一种新的程序性细胞死亡蛋白-配体1 （PD-L1）抑制剂，可以皮下给药。该方法治疗晚期高微卫星不稳定(MSI-H) /错配修复缺陷（dMMR）实体瘤是安全有效的。目前，程序性细胞死亡蛋白-1 (PD-1) /程序性细胞死亡蛋白配体1 （PD-L1）抑制剂治疗微卫星稳定型（MSS）肿瘤的疗效尚不清楚。我们报告一例晚期结肠癌合并双侧锁骨、纵隔、腹膜后、双侧门和左胸椎11/12椎体的MSS转移。经过8个月的恩伐利单抗治疗，转移性病变显著减少。截至2024年2月1日，患者未出现明显不良反应。目前疗效评价为部分缓解（PR），总生存期（OS）大于12个月。考虑到本病例观察到的恩伐利单抗的安全性和有效性，我们认为恩伐利单抗可能是治疗MSS转移性结肠癌的有希望的药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

OncoTargets and therapy BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ONCOLOGY

CiteScore

9.70

自引率

0.00%

发文量

221

审稿时长

1 months

期刊介绍： OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer. The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype. Specific topics covered by the journal include: -Novel therapeutic targets and innovative agents -Novel therapeutic regimens for improved benefit and/or decreased side effects -Early stage clinical trials Further considerations when submitting to OncoTargets and Therapy: -Studies containing in vivo animal model data will be considered favorably. -Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines. -Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples. -Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Single nucleotide polymorphism (SNP) studies will not be considered.